JPH0469606B2 - - Google Patents

Info

Publication number: JPH0469606B2
Authority: JP; Japan
Prior art keywords: neplanocin; htlv; virus; ebv; cells
Prior art date: 1984-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP27027484A

Other languages

English (en)

Japanese (ja)

Other versions

JPS61263919A (ja

Inventor

Toyoro Oosato

Masatoshi Tsujino

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Asahi Chemical Industry Co Ltd

Original Assignee

Asahi Chemical Industry Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-12-21

Filing date

1984-12-21

Publication date

1992-11-06

1984-12-21 Application filed by Asahi Chemical Industry Co Ltd filed Critical Asahi Chemical Industry Co Ltd

1984-12-21 Priority to JP27027484A priority Critical patent/JPS61263919A/ja

1986-11-21 Publication of JPS61263919A publication Critical patent/JPS61263919A/ja

1992-11-06 Publication of JPH0469606B2 publication Critical patent/JPH0469606B2/ja

Status Granted legal-status Critical Current

Links

UTCNWBUUZPUVLH-GBSPZJCNSA-N (1s,2s,3s,4s,5r)-4-(6-aminopurin-9-yl)-1-(hydroxymethyl)-6-oxabicyclo[3.1.0]hexane-2,3-diol Chemical compound NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@]2(CO)O[C@@H]21 UTCNWBUUZPUVLH-GBSPZJCNSA-N 0.000 claims description 40
UTCNWBUUZPUVLH-UHFFFAOYSA-N Neplanocin C Natural products NC1=NC=NC2=C1N=CN2C1C(O)C(O)C2(CO)OC21 UTCNWBUUZPUVLH-UHFFFAOYSA-N 0.000 claims description 40
241000700605 Viruses Species 0.000 claims description 14
239000004480 active ingredient Substances 0.000 claims description 6
239000003966 growth inhibitor Substances 0.000 claims description 4
241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
208000000389 T-cell leukemia Diseases 0.000 claims description 3
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 3
241000598436 Human T-cell lymphotropic virus Species 0.000 description 16
210000004027 cell Anatomy 0.000 description 13
239000000243 solution Substances 0.000 description 7
239000003443 antiviral agent Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 5
230000009422 growth inhibiting effect Effects 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
230000000694 effects Effects 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
230000009036 growth inhibition Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000126 substance Substances 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
-1 sucrose fatty acid ester Chemical class 0.000 description 2
239000000829 suppository Substances 0.000 description 2
HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000187844 Actinoplanes Species 0.000 description 1
241000187712 Actinoplanes sp. Species 0.000 description 1
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
244000260524 Chrysanthemum balsamita Species 0.000 description 1
235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
229930182507 Neplanocin Natural products 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
201000006966 adult T-cell leukemia Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000000748 compression moulding Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000002904 solvent Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP27027484A 1984-12-21 1984-12-21 ウイルス増殖抑制剤 Granted JPS61263919A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP27027484A JPS61263919A (ja)	1984-12-21	1984-12-21	ウイルス増殖抑制剤

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP27027484A JPS61263919A (ja)	1984-12-21	1984-12-21	ウイルス増殖抑制剤

Publications (2)

Publication Number	Publication Date
JPS61263919A JPS61263919A (ja)	1986-11-21
JPH0469606B2 true JPH0469606B2 (de)	1992-11-06

Family

ID=17483965

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP27027484A Granted JPS61263919A (ja)	1984-12-21	1984-12-21	ウイルス増殖抑制剤

Country Status (1)

Country	Link
JP (1)	JPS61263919A (de)

1984
- 1984-12-21 JP JP27027484A patent/JPS61263919A/ja active Granted

Also Published As

Publication number	Publication date
JPS61263919A (ja)	1986-11-21

Publication	Publication Date	Title
US5622959A (en)	1997-04-22	Method of treating retroviral infections in mammals
JPS63310819A (ja)	1988-12-19	抗レトロウイルス活性をもつ糖タンパク処理抑制剤
CA2066155A1 (en)	1992-02-03	Antiviral agent for human immunodeficiency virus
JPH02204414A (ja)	1990-08-14	２′，３′―ジデオキシプリンヌクレオシド／プリンヌクレオシドホスホリラーゼ阻害剤の組合せ療法および組成物
KR100484695B1 (ko)	2005-04-22	제약 조성물
CA2009505C (en)	1997-01-21	Inhibitor of herpesvirus adsorption
JPH0232093A (ja)	1990-02-01	抗レトロウィルスジフルオロ化ヌクレオシド類
EP0302263B1 (de)	1992-09-30	Therapeutikum zur Behandlung von AIDS
JPH0469606B2 (de)	1992-11-06
JPH0761946B2 (ja)	1995-07-05	エイズ・ウイルス増殖抑制剤
JP3002700B2 (ja)	2000-01-24	抗エイズウイルス剤
US4265910A (en)	1981-05-05	Isoprenylamines
EP1062947A1 (de)	2000-12-27	Arzneimittel für aids
US5955498A (en)	1999-09-21	Agent for prophylaxis and therapy of diseases
KR100227095B1 (ko)	1999-10-15	항 hiv제
US5283239A (en)	1994-02-01	Inhibitor of herpesvirus absorption
HU193217B (en)	1987-08-28	Process for producing active agents for immunemodulator compositions
JP2933229B2 (ja)	1999-08-09	エイズウイルスの増殖抑制剤
US20040142882A1 (en)	2004-07-22	Use of glycyrrhizin and its derivatives as RANTES inducers
JPH0551565B2 (de)	1993-08-03
JPH07509442A (ja)	1995-10-19	ウィルス病処置でのホスホリル化フラボノイド類
JPH07179347A (ja)	1995-07-18	抗ウイルス組成物
JPH01163121A (ja)	1989-06-27	抗レトロウイルス剤
JPH07206668A (ja)	1995-08-08	ヒト免疫不全ウイルス感染症治療剤
JPH0688904B2 (ja)	1994-11-09	ウイルスに対する増殖抑制剤